@article{271ca74e34df471b8dd88612e7c0b303,
title = "ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease",
abstract = "This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.",
keywords = "GvHD, acute, chronic, graft-versus-host disease, ruxolitinib",
author = "Nada Hamad and Ian Bilmon and Lynette Chee and Andrea Henden and Anna Johnston and Duncan Purtill and Ashish Bajel and Tey, {Siok Keen} and David Yeung and Theresa Cole and Clinton Lewis and Jason Butler",
note = "Funding Information: The authors thank Anne Dyson, MBBS, of WriteSource Medical Pty Ltd., Sydney, Australia, for providing medical writing support. The medical writing support was funded by Novartis Pharmaceuticals Australia Pty Limited, in accordance with Good Publication Practice (GPP 2022) guidelines ( https://www.ismpp.org/gpp-2022 ). Open access publishing facilitated by University of New South Wales, as part of the Wiley ‐ University of New South Wales agreement via the Council of Australian University Librarians. Publisher Copyright: {\textcopyright} 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",
year = "2023",
month = nov,
day = "28",
doi = "10.1111/imj.16255",
language = "English",
volume = "53",
pages = "2319--2329",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "John Wiley and Sons Inc.",
number = "12",
}